Michael J Flister1, Lisa D Volk, Sophia Ran. 1. Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9626, USA.
Abstract
OBJECTIVE: Inflammation and NF-κB are highly associated with lymphangiogenesis but the underlying mechanisms remain unclear. We recently established that activated NF-κB p50 subunit increases expression of the main lymphangiogenic mediators, VEGFR-3 and its transcriptional activator, Prox1. To elucidate the role of p50 in lymphatic vasculature, we compared LVD and phenotype in p50 KO and WT mice. METHODS: Normal tissues from KO and WT mice were stained for LYVE-1 to calculate LVD. VEGFR-3 and Prox1 expressions were analyzed by immunofluorescence and qRT-PCR. RESULTS: Compared with WT, LVD in the liver and lungs of KO mice was reduced by 39% and 13%, respectively. This corresponded to 25-44% decreased VEGFR-3 and Prox1 expression. In the MFP, LVD was decreased by 18% but VEGFR-3 and Prox1 expression was 80-140% higher than in WT. Analysis of p65 and p52 NF-κB subunits and an array of inflammatory mediators showed a significant increase in p50 alternative pathways in the MFP but not in other organs. CONCLUSIONS: These findings demonstrate the role of NF-κB p50 in regulating the expression of VEGFR-3, Prox1 and LVD in the mammary tissue, liver, and lung.
OBJECTIVE:Inflammation and NF-κB are highly associated with lymphangiogenesis but the underlying mechanisms remain unclear. We recently established that activated NF-κB p50 subunit increases expression of the main lymphangiogenic mediators, VEGFR-3 and its transcriptional activator, Prox1. To elucidate the role of p50 in lymphatic vasculature, we compared LVD and phenotype in p50 KO and WT mice. METHODS:Normal tissues from KO and WT mice were stained for LYVE-1 to calculate LVD. VEGFR-3 and Prox1 expressions were analyzed by immunofluorescence and qRT-PCR. RESULTS: Compared with WT, LVD in the liver and lungs of KO mice was reduced by 39% and 13%, respectively. This corresponded to 25-44% decreased VEGFR-3 and Prox1 expression. In the MFP, LVD was decreased by 18% but VEGFR-3 and Prox1 expression was 80-140% higher than in WT. Analysis of p65 and p52NF-κB subunits and an array of inflammatory mediators showed a significant increase in p50 alternative pathways in the MFP but not in other organs. CONCLUSIONS: These findings demonstrate the role of NF-κB p50 in regulating the expression of VEGFR-3, Prox1 and LVD in the mammary tissue, liver, and lung.
Authors: Tatiana V Petrova; Taija Mäkinen; Tomi P Mäkelä; Janna Saarela; Ismo Virtanen; Robert E Ferrell; David N Finegold; Dontscho Kerjaschki; Seppo Ylä-Herttuala; Kari Alitalo Journal: EMBO J Date: 2002-09-02 Impact factor: 11.598
Authors: Wenwu Cui; Stanislav I Tomarev; Joram Piatigorsky; Ana B Chepelinsky; Melinda K Duncan Journal: J Biol Chem Date: 2004-01-05 Impact factor: 5.157
Authors: Ido Paz-Priel; Dong Hong Cai; Dehua Wang; Jeanne Kowalski; Amanda Blackford; Huaitian Liu; Caroline A Heckman; Adrian F Gombart; H Phillip Koeffler; Linda M Boxer; Alan D Friedman Journal: Mol Cancer Res Date: 2005-10 Impact factor: 5.852
Authors: Antonella N Witmer; Jiapei Dai; Herbert A Weich; Gijs F J M Vrensen; Reinier O Schlingemann Journal: J Histochem Cytochem Date: 2002-06 Impact factor: 2.479
Authors: Ruolin Guo; Quan Zhou; Steven T Proulx; Ronald Wood; Rui-Cheng Ji; Christopher T Ritchlin; Bronislaw Pytowski; Zhenping Zhu; Yong-Jun Wang; Edward M Schwarz; Lianping Xing Journal: Arthritis Rheum Date: 2009-09
Authors: A Henno; S Blacher; C Lambert; A Colige; L Seidel; A Noël; C Lapière; M de la Brassinne; B V Nusgens Journal: Br J Dermatol Date: 2008-10-20 Impact factor: 9.302
Authors: Traci R Lyons; Virginia F Borges; Courtney B Betts; Qiuchen Guo; Puja Kapoor; Holly A Martinson; Sonali Jindal; Pepper Schedin Journal: J Clin Invest Date: 2014-08-18 Impact factor: 14.808
Authors: Michael J Flister; Shirng-Wern Tsaih; Alexander Stoddard; Cody Plasterer; Jaidip Jagtap; Abdul K Parchur; Gayatri Sharma; Anthony R Prisco; Angela Lemke; Dana Murphy; Mona Al-Gizawiy; Michael Straza; Sophia Ran; Aron M Geurts; Melinda R Dwinell; Andrew S Greene; Carmen Bergom; Peter S LaViolette; Amit Joshi Journal: Breast Cancer Res Treat Date: 2017-05-31 Impact factor: 4.872
Authors: Michael J Flister; Bradley T Endres; Nathan Rudemiller; Allison B Sarkis; Stephanie Santarriaga; Ishan Roy; Angela Lemke; Aron M Geurts; Carol Moreno; Sophia Ran; Shirng-Wern Tsaih; Jeffery De Pons; Daniel F Carlson; Wenfang Tan; Scott C Fahrenkrug; Zelmira Lazarova; Jozef Lazar; Paula E North; Peter S LaViolette; Michael B Dwinell; James D Shull; Howard J Jacob Journal: Cancer Res Date: 2014-08-29 Impact factor: 12.701
Authors: Qianqian Liang; Li Zhang; Ronald W Wood; Rui-Cheng Ji; Brendan F Boyce; Edward M Schwarz; Yongjun Wang; Lianping Xing Journal: Am J Pathol Date: 2019-09-17 Impact factor: 4.307